Currently out of the existing stock ratings of Prakhar Agrawal, 29 are a BUY (90.63%), 3 are a HOLD (9.38%).

Prakhar Agrawal

Work Performance Price Targets & Ratings Chart

Analyst Prakhar Agrawal works at CANTOR FITZGERALD with a stock forecast success ratio of 34.07% fulfilled within 77.85 days on average.

Prakhar Agrawal’s has documented 64 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RAPT, RAPT Therapeutics at 20-Feb-2024.

Wall Street Analyst Prakhar Agrawal

Analyst best performing recommendations are on NEXI (NEXIMMUNE).
The best stock recommendation documented was for DICE (DICE MOLECULES HOLDINGS LLC) at 9/14/2022. The price target of $36 was fulfilled within 27 days with a profit of $16.39 (83.58%) receiving and performance score of 30.96.

Average potential price target upside

ARNA Arena Pharmaceuticals LABP Landos Biopharma PHAT Phathom Pharmaceuticals OCUP Ocuphire Pharma EQ Equillium MLTX MoonLake Immunotherapeutics TGTX TG Therapeutics NEXI Neximmune PRVB Provention Bio DICE Dice Molecules Holdings LLC AKRO Akero Therapeutics CBAY Cymabay Therapeu RAPT RAPT Therapeutics

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

100

$0.01 (0.01%)

120

2 years 2 months 10 days ago

3/5 (60%)

$6.56 (7.02%)

256

Hold

100

2 years 3 months 23 days ago

4/6 (66.67%)

$9.27 (10.22%)

204

Hold

100

$0.01 (0.01%)

102

2 years 4 months 4 days ago

4/6 (66.67%)

$7.15 (7.70%)

247

Hold

79

2 years 4 months 4 days ago

5/5 (100%)

$33.14 (72.26%)

401

Hold

100

$0.01 (0.01%)

2 years 4 months 4 days ago

3/4 (75%)

$7.15 (7.70%)

557

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Prakhar Agrawal is most bullish on?

Potential upside of $31.73 has been obtained for MLTX (MOONLAKE IMMUNOTHERAPEUTICS)

Which stock is Prakhar Agrawal is most reserved on?

Potential downside of -$0 has been obtained for RAPT (RAPT THERAPEUTICS)

What Year was the first public recommendation made by Prakhar Agrawal?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?